| Autor: |
Basali, Diana, Chakraborty, Rajshekhar, Rybicki, Lisa, Rosko, Nathaniel, Reed, Janice, Karam, Maryann, Schlueter, Kristen, Dysert, Hayley, Kalaycio, Matt, Valent, Jason |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Jun2020, Vol. 189 Issue 6, p1136-1140, 5p, 2 Charts |
| Abstrakt: |
Summary: The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti‐apoptotic protein BCL‐2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax‐based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non‐haematologic toxicities, most commonly gastrointestinal upset, were observed. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text